WebSep 20, 2024 · The construction of prodrug and glucose oxidase coloaded alginate (ALG) hydrogels for PDT-combined chemotherapy of melanoma will provide a promising injectable hydrogel platform for effective treatments of cancer. Biomimetic nanoprodrugs from fatty acid modified camptothecin and albumin for enhanced pharmacotherapy. WebFeb 16, 2024 · The aim of this study was to prepare small-molecule camptothecin (CPT) prodrugs and evaluate their effectiveness in colorectal carcinoma therapy. Prodrug nanoparticles (NPs) were physicochemically characterized and evaluated for their cytotoxicity in human colon cancer (HCT116) cell lines. The antitumor efficacy of the NPs …
ROS‐Responsive Camptothecin Prodrug ... - Wiley Online …
WebSep 18, 2024 · Methotrexate–Camptothecin Prodrug Nanoassemblies as a Versatile Nanoplatform for Biomodal Imaging-Guided Self-Active Targeted and Synergistic Chemotherapy ACS Applied Materials & Interfaces ACS ACS Publications C&EN CAS Find my institution Log In Share Share on Facebook Twitter WeChat Linked In Reddit Email … WebCamptothecin and lactose act as the chemotherapy drug and targeting ligand in the drug delivery system, respectively. Since CPT-S-S-LA is an amphiphilic compound, it can self-assemble into nanoparticles with a diameter of around 110 nm. The CPT-S-S-LA nanoparticles displayed controllable drug release behavior in the physiological environment. church house grazeley
Development of a Prodrug of Camptothecin for Enhanced ... - PubMed
WebNov 28, 2024 · Camptothecin (CPT), a DNA topoisomerase I inhibitor that induces DNA damage in cancer cells, has been widely used for the treatment of a variety of cancers, … WebDec 1, 2024 · Self-assembled prodrugs (SAPDs), which combine prodrug strategy and the merits of self-assembly, not only represent an appealing type of therapeutics, enabling the spontaneous organization of supramolecular nanocomposites with defined structures in aqueous environments, but also provide a new method to formulate existing drugs for … WebJan 13, 2024 · Therapeutic conjugate approaches that alter the solubility of a conjugate “prodrug” have been used to enable NC formation and controlled release from NCs using labile linker chemistry. A limitation of this approach has been that a different linker chemistry must be used to produce an adjustable release rate for a single therapeutic. church house godalming